Adam Shlien

List of Publications by Year
in descending order

58 papers	9,648 citations	186265 28 h-index	197818 49 g-index
62 all docs	62 docs citations	62 times ranked	17377 citing authors

#	Article	IF	Citations
1	Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency. Nature Medicine, 2022, 28, 125-135.	30.7	53
2	Abstract LB177: Widespread hypertranscription in aggressive human cancer. Cancer Research, 2022, 82, LB177-LB177.	0.9	0
3	Signatures of copy number alterations in human cancer. Nature, 2022, 606, 984-991.	27.8	154
4	Abstract 5224: The PRecision Oncology For Young peopLE (PROFYLE) Program: A national precision oncology program for children, adolescents and young adults with hard-to-cure cancer in Canada. Cancer Research, 2022, 82, 5224-5224.	0.9	1
5	TERT promotor variant associated with poor clinical outcome in a patient with novel RBM15â€MKL1 fusionâ€positive pediatric acute megakaryoblastic leukemia. Pediatric Blood and Cancer, 2021, 68, e28542.	1.5	5
6	Pathogenic Germline Variants in Cancer Susceptibility Genes in Children and Young Adults With Rhabdomyosarcoma. JCO Precision Oncology, 2021, 5, 75-87.	3.0	27
7	Mutations in the RAS/MAPK Pathway Drive Replication Repairâ€“Deficient Hypermutated Tumors and Confer Sensitivity to MEK Inhibition. Cancer Discovery, 2021, 11, 1454-1467.	9.4	19
8	Nonâ€rhabdomyosarcoma soft tissue sarcomas diagnosed in patients at a young age. An overview of clinical, pathological, and molecular findings. Pediatric Blood and Cancer, 2021, 68, e29022.	1.5	0
9	Resolving driver events in MLL-r negative high-risk infant ALL.. Journal of Clinical Oncology, 2021, 39, 10030-10030.	1.6	0
10	Clonal hematopoiesis and therapy-related myeloid neoplasms following neuroblastoma treatment. Blood, 2021, 137, 2992-2997.	1.4	19
11	Single cell derived mRNA signals across human kidney tumors. Nature Communications, 2021, 12, 3896.	12.8	27
12	Lineage-defined leiomyosarcoma subtypes emerge years before diagnosis and determine patient survival. Nature Communications, 2021, 12, 4496.	12.8	28
13	Ethical and Analytic Challenges With Genomic Sequencing of Relapsed Hematologic Malignancies Following Allogeneic Hematopoietic Stem-Cell Transplantation. JCO Precision Oncology, 2021, 5, 1339-1347.	3.0	2
14	Diverse Oncogenic Fusions and Distinct Gene Expression Patterns Define the Genomic Landscape of Pediatric Papillary Thyroid Carcinoma. Cancer Research, 2021, 81, 5625-5637.	0.9	15
15	DNA Polymerase and Mismatch Repair Exert Distinct Microsatellite Instability Signatures in Normal and Malignant Human Cells. Cancer Discovery, 2021, 11, 1176-1191.	9.4	46
16	Performance of the McGill Interactive Pediatric OncoGenetic Guidelines for Identifying Cancer Predisposition Syndromes. JAMA Oncology, 2021, 7, 1806.	7.1	22
17	Abstract P136: Response to alpelisib in an adolescent with PIK3CA-mutated metastatic gastrointestinal stromal tumour. , 2021, , .		0
18	First report of t(5;11) KMT2A-MAML1 fusion in de novo infant acute lymphoblastic leukemia. Cancer Genetics, 2020, 248-249, 31-33.	0.4	3

#	Article	IF	Citations
19	Cancers from Novel Pole-Mutant Mouse Models Provide Insights into Polymerase-Mediated Hypermutagenesis and Immune Checkpoint Blockade. Cancer Research, 2020, 80, 5606-5618.	0.9	14
20	A slipped-CAG DNA-binding small molecule induces trinucleotide-repeat contractions in vivo. Nature Genetics, 2020, 52, 146-159.	21.4	110
21	IMMU-18. FAVORABLE OUTCOME IN REPLICATION REPAIR DEFICIENT HYPERMUTANT BRAIN TUMORS TO IMMUNE CHECKPOINT INHIBITION: AN INTERNATIONAL RRD CONSORTIUM REGISTRY STUDY. Neuro-Oncology, 2020, 22, iii363-iii363.	1.2	1
22	DNA methylation signature is prognostic of choroid plexus tumor aggressiveness. Clinical Epigenetics, 2019, 11, 117.	4.1	21
23	Cooperation of cancer drivers with regulatory germline variants shapes clinical outcomes. Nature Communications, 2019, 10, 4128.	12.8	51
24	IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL REPLICATION REPAIR DEFICIENCY CONSORTIUM. Neuro-Oncology, 2019, 21, ii96-ii97.	1.2	0
25	TMOD-10. REPLICATION REPAIR DEFICIENT MOUSE MODELS PROVIDE INSIGHT ON HYPERMUTANT BRAIN TUMOURS AND COMBINATIONAL IMMUNOTHERAPY. Neuro-Oncology, 2019, 21, ii123-ii123.	1.2	0
26	mTOR Inhibitors as a New Therapeutic Strategy in Treatment Resistant Epilepsy in Hemimegalencephaly: A Case Report. Journal of Child Neurology, 2019, 34, 132-138.	1.4	24
27	Immune signature and molecular profiling of radiation-induced sarcoma (RIS).. Journal of Clinical Oncology, 2019, 37, 11040-11040.	1.6	3
28	Cellular and Molecular Architecture of Hematopoietic Stem Cells and Progenitors in Genetic Models of Bone Marrow Failure. Blood, 2019, 134, 1223-1223.	1.4	0
29	DICER1 Mutations Are Frequent in Adolescent-Onset Papillary Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 2009-2015.	3.6	79
30	Aggressive embryonal rhabdomyosarcoma in a 3-month-old boy: A clinical and molecular analysis. Pediatric Hematology and Oncology, 2018, 35, 407-414.	0.8	0
31	HGG-17. TUMOR MUTATIONAL BURDEN ANALYSIS OF PEDIATRIC TUMORS PROVIDES A DIAGNOSTIC TOOL FOR GERMLINE REPLICATION REPAIR DEFICIENCY AND PREDICT RESPONSE TO IMMUNE CHECKPOINT INHIBITION. Neuro-Oncology, 2018, 20, i92-i92.	1.2	0
32	EAPH-06. HYPERMUTANT PEDIATRIC HIGH GRADE GLIOMAS ARE DRIVEN BY RAS/MAPK MUTATIONS AND RESPOND TO MEK INHIBITION. Neuro-Oncology, 2018, 20, i66-i66.	1.2	0
33	Rearrangement bursts generate canonical gene fusions in bone and soft tissue tumors. Science, 2018, 361, .	12.6	121
34	Optimized knock-in of point mutations in zebrafish using CRISPR/Cas9. Nucleic Acids Research, 2018, 46, e102-e102.	14.5	50
35	Response to Immune Checkpoint Inhibition in Two Patients with Alveolar Soft-Part Sarcoma. Cancer Immunology Research, 2018, 6, 1001-1007.	3.4	50
36	Explosive mutation accumulation triggered by heterozygous human Pol Îµ proofreading-deficiency is driven by suppression of mismatch repair. ELife, 2018, 7, .	6.0	33

#	Article	IF	Citations
37	Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Medicine, 2017, 9, 34.	8.2	2,480
38	Recurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma. Nature Communications, 2017, 8, 15936.	12.8	179
39	The driver landscape of sporadic chordoma. Nature Communications, 2017, 8, 890.	12.8	115
40	Comprehensive Analysis of Hypermutation in Human Cancer. Cell, 2017, 171, 1042-1056.e10.	28.9	596
41	Germline and somatic mutations in STXBP1 with diverse neurodevelopmental phenotypes. Neurology: Genetics, 2017, 3, e199.	1.9	41
42	Immunoprofiling in alveolar soft part sarcoma.. Journal of Clinical Oncology, 2017, 35, 11059-11059.	1.6	6
43	Direct Transcriptional Consequences of Somatic Mutation in Breast Cancer. Cell Reports, 2016, 16, 2032-2046.	6.4	36
44	Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency. Journal of Clinical Oncology, 2016, 34, 2206-2211.	1.6	692
45	Translational Childhood Cancer Genomics. JAMA Oncology, 2016, 2, 384.	7.1	1
46	MG-129â€...Our experience ofin silicogene panel testing for clinically heterogeneous disorders using exome sequencing. Journal of Medical Genetics, 2015, 52, A11.1-A11.	3.2	1
47	MG-130â€...Utilising whole exome sequencing to identify causative variants in genetically heterogeneous disorders. Journal of Medical Genetics, 2015, 52, A11.2-A11.	3.2	0
48	BRAF Mutation and CDKN2A Deletion Define a Clinically Distinct Subgroup of Childhood Secondary High-Grade Glioma. Journal of Clinical Oncology, 2015, 33, 1015-1022.	1.6	244
49	Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers. Nature Genetics, 2015, 47, 257-262.	21.4	306
50	Molecular Characterization of Choroid Plexus Tumors Reveals Novel Clinically Relevant Subgroups. Clinical Cancer Research, 2015, 21, 184-192.	7.0	84
51	Long read nanopore sequencing for detection of HLA and CYP2D6 variants and haplotypes. F1000Research, 2015, 4, 17.	1.6	55
52	Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer. Nature Genetics, 2014, 46, 487-491.	21.4	254
53	Mutational Processes Molding the Genomes of 21 Breast Cancers. Cell, 2012, 149, 979-993.	28.9	1,673
54	The Life History of 21 Breast Cancers. Cell, 2012, 149, 994-1007.	28.9	1,249

#	Article	IF	Citations
55	Copy number variations and cancer susceptibility. Current Opinion in Oncology, 2010, 22, 55-63.	2.4	69
56	A Common Molecular Mechanism Underlies Two Phenotypically Distinct 17p13.1 Microdeletion Syndromes. American Journal of Human Genetics, 2010, 87, 631-642.	6.2	36
57	Copy number variations and cancer. Genome Medicine, 2009, 1, 62.	8.2	304
58	Excessive genomic DNA copy number variation in the Liâ€“Fraumeni cancer predisposition syndrome. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 11264-11269.	7.1	192